Ipilimumab and Nivolumab for the Treatment of Stage III-IV Unresectable Metastatic Melanoma

Clinical trial NCT04967196 · TERMINATED

Trial details

NCT number: NCT04967196
Sponsor: Mayo Clinic
Status: TERMINATED
Phase: Phase 1
Study type: INTERVENTIONAL

Clinical Stage III Cutaneous Melanoma AJCC v8 Clinical Stage IV Cutaneous Melanoma AJCC v8 Metastatic Melanoma Unresectable Melanoma

Start date: 2021-09-16
Primary completion: 2024-04-17
Enrollment: 6

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.